165 related articles for article (PubMed ID: 38760444)
1. Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer.
Treekitkarnmongkol W; Shah V; Kai K; Katayama H; Wong J; Ladha FA; Nguyen T; Menegaz B; Lu W; Yang F; Mino B; Tang X; Gagea M; Batra H; Raso MG; Wistuba II; Krishnamurthy S; Pinder SE; Sawyer EJ; Thompson AM; Sen S
Br J Cancer; 2024 May; ():. PubMed ID: 38760444
[TBL] [Abstract][Full Text] [Related]
2. SOX11 promotes invasive growth and ductal carcinoma in situ progression.
Oliemuller E; Kogata N; Bland P; Kriplani D; Daley F; Haider S; Shah V; Sawyer EJ; Howard BA
J Pathol; 2017 Oct; 243(2):193-207. PubMed ID: 28707729
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial.
Thorat MA; Levey PM; Jones JL; Pinder SE; Bundred NJ; Fentiman IS; Cuzick J
Clin Cancer Res; 2021 Oct; 27(19):5317-5324. PubMed ID: 34380636
[TBL] [Abstract][Full Text] [Related]
4. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
Solin LJ; Gray R; Baehner FL; Butler SM; Hughes LL; Yoshizawa C; Cherbavaz DB; Shak S; Page DL; Sledge GW; Davidson NE; Ingle JN; Perez EA; Wood WC; Sparano JA; Badve S
J Natl Cancer Inst; 2013 May; 105(10):701-10. PubMed ID: 23641039
[TBL] [Abstract][Full Text] [Related]
5. Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ.
Guerini-Rocco E; Bellerba F; Concardi A; Taormina SV; Cammarata G; Fumagalli C; Guerrieri-Gonzaga A; Macis D; Del Fiol Manna E; Balladore E; Cannone M; Veronesi P; Fusco N; Bonanni B; Viale G; Barberis M; Gandini S; Lazzeroni M
Eur J Cancer; 2024 May; 203():114063. PubMed ID: 38615592
[TBL] [Abstract][Full Text] [Related]
6. Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy.
Yang L; Shen M; Qiu Y; Tang T; Bu H
Breast; 2022 Aug; 64():1-6. PubMed ID: 35462343
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.
Zhou W; Jirström K; Johansson C; Amini RM; Blomqvist C; Agbaje O; Wärnberg F
BMC Cancer; 2010 Nov; 10():653. PubMed ID: 21118480
[TBL] [Abstract][Full Text] [Related]
8. EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer.
Knudsen ES; Dervishaj O; Kleer CG; Pajak T; Schwartz GF; Witkiewicz AK
Cell Cycle; 2013 Jul; 12(13):2042-50. PubMed ID: 23759596
[TBL] [Abstract][Full Text] [Related]
9. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
[TBL] [Abstract][Full Text] [Related]
10. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
11. HER2 overexpression in ductal carcinoma in situ is associated with ipsilateral breast cancer recurrence after conservative surgery.
Gong DH; Ge JY; Chen YY; Ding KF; Yu KD
Transl Cancer Res; 2020 Jun; 9(6):3787-3793. PubMed ID: 35117746
[TBL] [Abstract][Full Text] [Related]
12. Higher densities of tumour-infiltrating lymphocytes and CD4
Thike AA; Chen X; Koh VCY; Binte Md Nasir ND; Yeong JPS; Bay BH; Tan PH
Histopathology; 2020 May; 76(6):852-864. PubMed ID: 31883279
[TBL] [Abstract][Full Text] [Related]
13. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.
Solin LJ; Gray R; Hughes LL; Wood WC; Lowen MA; Badve SS; Baehner FL; Ingle JN; Perez EA; Recht A; Sparano JA; Davidson NE
J Clin Oncol; 2015 Nov; 33(33):3938-44. PubMed ID: 26371148
[TBL] [Abstract][Full Text] [Related]
14. Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness.
Zheng ZY; Elsarraj H; Lei JT; Hong Y; Anurag M; Feng L; Kennedy H; Shen Y; Lo F; Zhao Z; Zhang B; Zhang XH; Tawfik OW; Behbod F; Chang EC
Breast Cancer Res; 2022 Oct; 24(1):68. PubMed ID: 36258226
[TBL] [Abstract][Full Text] [Related]
15. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
Choi YJ; Shin YD; Song YJ
World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
[TBL] [Abstract][Full Text] [Related]
17. A Comparison of Predicted Ipsilateral Tumor Recurrence Risks in Patients With Ductal Carcinoma in Situ of the Breast After Breast-Conserving Surgery by Breast Radiation Oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS Nomogram, and the 12-Gene DCIS Score Assay.
Lei RY; Carter DL; Antell AG; Nowels MA; Tole SP; Bennett JP; Turner M; Baehner FL; Leonard CE
Adv Radiat Oncol; 2021; 6(2):100607. PubMed ID: 33912731
[TBL] [Abstract][Full Text] [Related]
18. Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.
Thompson AM; Clements K; Cheung S; Pinder SE; Lawrence G; Sawyer E; Kearins O; Ball GR; Tomlinson I; Hanby A; Thomas JSJ; Maxwell AJ; Wallis MG; Dodwell DJ;
Eur J Cancer; 2018 Sep; 101():210-219. PubMed ID: 30092498
[TBL] [Abstract][Full Text] [Related]
19. The clinical significance of HER2 expression in DCIS.
Akrida I; Mulita F
Med Oncol; 2022 Nov; 40(1):16. PubMed ID: 36352293
[TBL] [Abstract][Full Text] [Related]
20. Breast ductal Carcinoma in situ associated with microinvasion induces immunological response and predicts ipsilateral invasive recurrence.
Chen XY; Thike AA; Koh VCY; Nasir NDM; Bay BH; Tan PH
Virchows Arch; 2021 Apr; 478(4):679-686. PubMed ID: 33140128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
